Avanir Licenses Concert’s Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 3 (Table of Contents)
Published: 12 Mar-2012
DOI: 10.3833/pdr.v2012.i3.1696 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a deal that could be worth more than US$200 M, Avanir Pharmaceuticals has licensed global rights to Concert Pharmaceuticals’ multiple deuterium-modified dextromethorphan (d-DM) products for the potential treatment of neurological and psychiatric disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS